Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorization Safety Study to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy in North America

NCT04173442 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04173442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04173442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorization Safety Study to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy in North America
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
October 24, 2018
Completion date
November 4, 2025
Enrollment
581 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, atopic dermatitis (ad)